-
Precigen Opens Cell Therapy Mfg. Facility in MD
contractpharma
April 28, 2019
Precigen, Inc., a wholly-owned subsidiary of Intrexon Corp. and a clinical stage biopharmaceutical company specializing in the development of gene and cellular therapies has opened its new manufacturing facility in Germantown, MD.
-
Orgenesis, ExcellaBio Enter Cell Therapy Tie-up
contractpharma
April 18, 2019
Orgenesis, a developer, manufacturer and service provider of advanced cell therapies, has entered into a collaboration and licensing agreement with ...
-
Immatics, Roche ally to trial Tecentriq with cell therapy
fiercebiotech
February 27, 2019
Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors....
-
Cell therapy produces encouraging first results in eye trial
pharmaphorum
February 26, 2019
UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP).
-
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies
pharmafocusasia
January 21, 2019
Obsidian Therapeutics, a biotechnology company developing cell therapies with pharmacologic operating systems, today announced a strategic collaboration with ....
-
Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH
fiercebiotech
January 03, 2019
Shares of cell therapy developer Fate Therapeutics shot up more than 8% Friday morning to $15.31 after the company announced that the FDA accepted its IND application for a ......
-
Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population
americanpharmaceuticalreview
December 10, 2018
Intellia Therapeutics, Inc., a genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo.....
-
Oxford BioMedica unveils digital initiative to streamline manufacturing
pharmatimes
November 26, 2018
UK gene and cell therapy group Oxford BioMedica has announced a new digital framework initiative to streamline the production of next-generation medicines.
-
Xiangxue Pharma to build cell therapy facility
biospectrumasia
June 11, 2018
XPH is focused on cancer treatments based on a new-generation TCR T-cell therapy.
-
Celixir’s cell therapy gets green light for heart failure trial
pharmatimes
January 10, 2018
The Medicines and Healthcare Products Regulatory Agency has issued a green light allowing Celixir to carry out a potentially pivotal Phase IIb human clinical trial with its stem cell therapy Heartcel.